David J Kerr CBE MD DSc FRCP(Glas,Lon,Edin) FRCGP FMedSci is Professor of Cancer Medicine, University of Oxford, Adjunct Professor of Medicine, Weill-Cornell College of Medicine and Honorary Professor, University of Xiamen and 2nd Military University, Shanghai. He has a long standing interest in the biology and treatment of colorectal cancer and has contributed many publications to this field. He is former President of the European Society of Medical Oncology and is currently Editor in Chief of the Journal of Global Oncology.Dr Rebecca Johnson is a junior doctor working at Oxford University Hospitals NHS Foundation Trust.  Rebecca holds a Bachelor of Science degree in Genetics and a PhD in DNA double strand break repair. Rebecca was awarded the Irvington Fellowship of the Cancer Research Institute of the United States of America, for work investigating the initiating molecular lesions of common malignancies, this award was tenured at New York University. Following this postdoctoral fellowship, she studied medicine at the University of Birmingham and has recently entered the Core Medical training programme.

• Introduction to modern immunology.- Cell based therapy – modified cancer cells.- Vaccines for GI cancer.-  Antibody delivery of radioactive ‘warheads’ and cytotoxins.- Antibodies which inhibit specific cell pathways.- PD1 and PD1l immune checkpoint inhibitors.- The Role of the JAK/STAT Signaling Pathway in Immunoregulation of Gastrointestinal Cancers.- Hyper mutated colorectal cancer and neoantigen load.- Antibodies which inhibit specific cell pathways,  colorectal  cancer.

David J Kerr CBE MD DSc FRCP(Glas,Lon,Edin) FRCGP FMedSci is Professor of Cancer Medicine, University of Oxford, Adjunct Professor of Medicine, Weill-Cornell College of Medicine and Honorary Professor, University of Xiamen and 2nd Military University, Shanghai. He has a long standing interest in the biology and treatment of colorectal cancer and has contributed many publications to this field. He is former President of the European Society of Medical Oncology and is currently Editor in Chief of the Journal of Global Oncology.Dr Rebecca Johnson is a junior doctor working at Oxford University Hospitals NHS Foundation Trust.  Rebecca holds a Bachelor of Science degree in Genetics and a PhD in DNA double strand break repair. Rebecca was awarded the Irvington Fellowship of the Cancer Research Institute of the United States of America, for work investigating the initiating molecular lesions of common malignancies, this award was tenured at New York University. Following this postdoctoral fellowship, she studied medicine at the University of Birmingham and has recently entered the Core Medical training programme.

• Introduction to modern immunology.- Cell based therapy – modified cancer cells.- Vaccines for GI cancer.-  Antibody delivery of radioactive ‘warheads’ and cytotoxins.- Antibodies which inhibit specific cell pathways.- PD1 and PD1l immune checkpoint inhibitors.- The Role of the JAK/STAT Signaling Pathway in Immunoregulation of Gastrointestinal Cancers.- Hyper mutated colorectal cancer and neoantigen load.- Antibodies which inhibit specific cell pathways,  colorectal  cancer.

David J Kerr CBE MD DSc FRCP(Glas,Lon,Edin) FRCGP FMedSci is Professor of Cancer Medicine, University of Oxford, Adjunct Professor of Medicine, Weill-Cornell College of Medicine and Honorary Professor, University of Xiamen and 2nd Military University, Shanghai. He has a long standing interest in the biology and treatment of colorectal cancer and has contributed many publications to this field. He is former President of the European Society of Medical Oncology and is currently Editor in Chief of the Journal of Global Oncology.Dr Rebecca Johnson is a junior doctor working at Oxford University Hospitals NHS Foundation Trust.  Rebecca holds a Bachelor of Science degree in Genetics and a PhD in DNA double strand break repair. Rebecca was awarded the Irvington Fellowship of the Cancer Research Institute of the United States of America, for work investigating the initiating molecular lesions of common malignancies, this award was tenured at New York University. Following this postdoctoral fellowship, she studied medicine at the University of Birmingham and has recently entered the Core Medical training programme.

• Introduction to modern immunology.- Cell based therapy – modified cancer cells.- Vaccines for GI cancer.-  Antibody delivery of radioactive ‘warheads’ and cytotoxins.- Antibodies which inhibit specific cell pathways.- PD1 and PD1l immune checkpoint inhibitors.- The Role of the JAK/STAT Signaling Pathway in Immunoregulation of Gastrointestinal Cancers.- Hyper mutated colorectal cancer and neoantigen load.- Antibodies which inhibit specific cell pathways,  colorectal  cancer.